thalidomide has been researched along with Cardiomyopathy, Congestive in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD)." | 9.11 | Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. ( Andreassen, A; Aukrust, P; Breivik, K; Fjeld, JG; Frøland, SS; Følling, M; Gullestad, L; Gundersen, T; Hodt, A; Holt, E; Kjekshus, E; Kjekshus, J; Semb, AG; Skårdal, R; Ueland, T; Wergeland, R; Yndestad, A, 2005) |
| "Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD)." | 5.11 | Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. ( Andreassen, A; Aukrust, P; Breivik, K; Fjeld, JG; Frøland, SS; Følling, M; Gullestad, L; Gundersen, T; Hodt, A; Holt, E; Kjekshus, E; Kjekshus, J; Semb, AG; Skårdal, R; Ueland, T; Wergeland, R; Yndestad, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gullestad, L | 1 |
| Ueland, T | 1 |
| Fjeld, JG | 1 |
| Holt, E | 1 |
| Gundersen, T | 1 |
| Breivik, K | 1 |
| Følling, M | 1 |
| Hodt, A | 1 |
| Skårdal, R | 1 |
| Kjekshus, J | 1 |
| Andreassen, A | 1 |
| Kjekshus, E | 1 |
| Wergeland, R | 1 |
| Yndestad, A | 1 |
| Frøland, SS | 1 |
| Semb, AG | 1 |
| Aukrust, P | 1 |
1 trial available for thalidomide and Cardiomyopathy, Congestive
| Article | Year |
|---|---|
Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study.
Topics: Aged; Cardiomyopathy, Dilated; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow | 2005 |